Eli Lilly & Company | Eli Lilly | Indiana | state | 2022 | $293,100,000 | | MEGADEAL |
Eli Lilly | Eli Lilly | Indiana | multiple | 1999 | $214,000,000 | | MEGADEAL |
AstraZeneca | AstraZeneca | Delaware | multiple | 1999 | $178,000,000 | | MEGADEAL |
Elanco Animal Health Inc | Elanco Animal Health | Indiana | multiple | 2020 | $163,100,000 | | MEGADEAL |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | multiple | 2018 | $155,700,000 | | MEGADEAL |
Amylin Pharmaceuticals | AstraZeneca | Ohio | multiple | 2007 | $117,000,000 | | MEGADEAL |
Novo Nordisk | Novo Holdings A/S | North Carolina | multiple | 2016 | $109,900,000 | | MEGADEAL |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | multiple | 2021 | $107,700,000 | | MEGADEAL |
Pfizer | Pfizer | Michigan | multiple | 2001 | $84,200,000 | | MEGADEAL (Archived) |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | multiple | 2008 | $74,786,338 | | MEGADEAL (Archived) |
Vertex Pharmaceuticals | Vertex Pharmaceuticals | Massachusetts | multiple | 2011 | $72,000,000 | | MEGADEAL (Archived) |
Regeneron Pharmaceuticals, Inc. (CD#3) | Regeneron Pharmaceuticals | New York | state | 2019 | $70,000,000 | | tax credit/rebate |
Bristol-Myers Squibb | Bristol-Myers Squibb | Massachusetts | state | 2006 | $67,000,000 | | MEGADEAL (Archived) |
Pfizer | Pfizer | Connecticut | multiple | 1998 | $60,000,000 | | MEGADEAL (Archived) |
Allergan Sales, LLC | AbbVie | New Jersey | state | 2016 | $58,284,000 | | tax credit/rebate |
Allergan Sales, LLC | AbbVie | New Jersey | state | 2016 | $58,284,000 | | MEGADEAL (Archived) |
Alexion Pharmaceuticals | AstraZeneca | Connecticut | state | 2012 | $51,000,000 | | tax credit/rebate |
Teva Pharmceuticals USA Inc. | Teva Pharmaceutical Industries | New Jersey | State | 2018 | $39,998,730 | | tax credit/rebate |
Biovail Americas Corporation and subsidiaries | Bausch Health | New Jersey | state | 2013 | $39,502,500 | | tax credit/rebate |
ImClone Systems Corporation | Eli Lilly | New Jersey | state | 2008 | $32,363,676 | | grant |
Novozymes Blair, Inc. | Novo Holdings A/S | United States | federal | 2010 | $28,401,000 | | federal allocated tax credit |
Alexion Pharmaceuticals, Inc | AstraZeneca | Connecticut | state | 2013 | $26,000,000 | | grant/loan hybrid program |
Alexion Pharmaceuticals, Inc. | AstraZeneca | Connecticut | state | 2016 | $25,000,000 | | tax credit/rebate |
Amyris, Inc. | Amyris | United States | federal | 2009 | $24,341,409 | | federal grant |
Merck & Co., Inc. | Merck | North Carolina | state | 2004 | $24,000,000 | | grant/loan hybrid program |
Sanofi-Aventis U.S. LLC and Sanofi-Aventis U.S. In | Sanofi | New Jersey | state | 1999 | $21,795,200 | | grant |
Perrigo Company | Perrigo | Michigan | state | 2013 | $21,463,000 | | property tax abatement |
Novo Nordisk Pharmaceutical Industries, Inc. | Novo Holdings A/S | North Carolina | state | 2015 | $21,149,000 | | grant |
Merck, Sharp & Dohme Corp. | Merck | Pennsylvania | state | 2011 | $19,590,893 | | tax credit/rebate |
Zoetis Inc. and Subsidiaries | Zoetis | New Jersey | state | 2012 | $19,250,000 | | grant |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2008 | $18,128,934 | | tax credit/rebate |
Eli Lilly and Company II | Eli Lilly | North Carolina | state | 2022 | $16,169,000 | | grant |
OSI Pharmaceuticals | Astellas Pharma | New York | state | 2010 | $15,000,000 | | grant |
Amgen Inc. | Amgen | Ohio | state | 2021 | $15,000,000 | | tax credit/rebate |
Allergan Sales, LLC | AbbVie | New Jersey | state | 2011 | $14,906,273 | | grant |
Perrigo Company | Perrigo | Michigan | state | 2013 | $14,315,000 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | local | 2014 | $13,628,726 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | local | 2015 | $13,628,726 | | tax credit/rebate |
Biogen Idec US Limited Partnership | Biogen | North Carolina | state | 2009 | $12,564,345 | | tax credit/rebate |
Pharmacia & Upjohn Company | Pfizer | New Jersey | state | 1998 | $12,500,000 | | grant |
SIGMA-ALDRICH BIOTECHNOLOGY L.P. | Merck KGaA (EMD) | Missouri | state | 2001 | $12,298,727 | | tax credit/rebate |
Merck Sharp & Dohme Corp. | Merck | North Carolina | state | 2015 | $12,098,272 | | tax credit/rebate |
Elanco Us Inc. | Elanco Animal Health | Indiana | state | 2021 | $12,000,000 | | tax credit/rebate |
Amgen Inc. | Amgen | North Carolina | state | 2021 | $11,612,250 | | grant |
Incyte Corporation | Incyte Corp. | Delaware | state | 2012 | $11,120,505 | | grant/loan hybrid program |
Novartis #3 | Novartis | New Jersey | state | 2006 | $11,060,671 | | Tax credit/rebate |
Pfizer | Pfizer | New York | local | 2003 | $10,401,000 | | tax credit/rebate; property tax abatement |
Merck, Sharp & Dohme Corp. | Merck | Pennsylvania | state | 2012 | $10,263,039 | | tax credit/rebate |
Mallinckrodt Enterprises, LLC | Mallinckrodt | New Jersey | state | 2016 | $10,212,500 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | state | 2015 | $10,200,000 | | tax credit/rebate |
Gilead Sciences, Inc. | Gilead Sciences | North Carolina | state | 2021 | $9,997,500 | | grant |
Novozymes, Inc. | Novo Holdings A/S | United States | federal | 2008 | $9,994,970 | | federal grant |
Elanco Us Inc. | Elanco Animal Health | Indiana | state | 2021 | $9,750,000 | | tax credit/rebate |
Pfizer Inc. | Pfizer | New Jersey | state | 2010 | $9,182,250 | | grant |
Sandoz Inc. | Sandoz Group | New Jersey | state | 2014 | $9,180,000 | | tax credit/rebate |
Bausch & Lomb Incorporated | Bausch Health | New York | state | 2015 | $9,000,000 | | tax credit/rebate |
Vertex Pharmaceuticals | Vertex Pharmaceuticals | Massachusetts | local | 2015 | $9,000,000 | | tax increment financing |
Pharmacia Corporation, Affiliates and Subsidiaries | Pfizer | New Jersey | state | 2001 | $8,752,000 | | grant |
Eli Lilly and Company | Eli Lilly | North Carolina | state | 2020 | $8,689,500 | | grant |
GlaxoSmithkline Holdings Americas , Inc. | GlaxoSmithKline | North Carolina | state | 2015 | $8,524,608 | | tax credit/rebate |
Sanofi-Aventis U.S. LLC and Sanofi-Aventis U.S. | Sanofi | New Jersey | state | 2005 | $8,369,000 | | grant |
King Pharmaceuticals, Inc. | Pfizer | New Jersey | state | 2005 | $8,253,750 | | grant |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2018 | $8,135,140 | | tax credit/rebate |
Novartis Vaccines & Diagnostics | Novartis | North Carolina | state | 2006 | $8,015,000 | | grant |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2019 | $7,847,528 | | tax credit/rebate |
Janssen Research & Development LLC | Johnson & Johnson | Pennsylvania | state | 2021 | $7,844,600 | | tax credit/rebate |
MedImmune Inc. | AstraZeneca | Maryland | state | 2006 | $7,500,000 | | grant/loan hybrid program |
Merck & Co., Inc. | Merck | Virginia | state | 2019 | $7,500,000 | | grant |
Novartis Vaccines & Diagnostics, Inc. | Novartis | North Carolina | state | 2015 | $7,125,021 | | tax credit/rebate |
Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | Florida | local | 2016 | $7,100,000 | | grant |
Kite Pharma, Inc. | Gilead Sciences | California | state | 2016 | $7,000,000 | | tax credit/rebate |
Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | Florida | local | 2021 | $7,000,000 | | grant |
Exelixis, Inc. | Exelixis | California | state | 2020 | $7,000,000 | | tax credit/rebate |
Novartis Vaccines & Diagnostics, Inc. | Novartis | North Carolina | state | 2011 | $6,896,304 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | state | 2015 | $6,700,000 | | tax credit/rebate |
Merck & Co., Inc. | Merck | North Carolina | state | 2012 | $6,651,352 | | tax credit/rebate |
JANSSEN RESEARCH & DEVELOPMENT LLC | Johnson & Johnson | Pennsylvania | state | 2020 | $6,332,600 | | tax credit/rebate |
Biogen Idec | Biogen | Massachusetts | state | 2014 | $6,250,000 | | tax credit/rebate |
Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | 2014 | $6,118,950 | | tax credit/rebate |
Celgene Corporation | Bristol-Myers Squibb | New Jersey | state | 2004 | $6,086,250 | | grant |
Merck & Co., Inc. | Merck | North Carolina | state | 2010 | $6,007,498 | | tax credit/rebate |
NewLink Genetics, Inc. | Lumos Pharma | Iowa | state | 2004 | $6,000,000 | | grant |
Merck & Co., Inc. | Merck | Texas | state | 2017 | $6,000,000 | | grant |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $6,000,000 | | tax credit/rebate |
ZYMOGENETICS, INC. | Bristol-Myers Squibb | Washington | state | 2017 | $5,971,568 | | tax credit/rebate |
Shire HGT, Inc. | Takeda Pharmaceutical | Massachusetts | state | 2011 | $5,855,368 | | tax credit/rebate |
Novartis Pharmaceuticals Corporation ("NPC") | Novartis | New Jersey | state | 2004 | $5,822,250 | | grant |
Janssen Research & Development, LLC | Johnson & Johnson | Pennsylvania | state | 2016 | $5,695,092 | | tax credit/rebate |
Albany Molecular Research, Inc. | Curia Inc. | New York | state | 2003 | $5,679,250 | | enterprise zone |
Aralez Pharmaceuticals US, Inc. | Miravo Healthcare | New Jersey | state | 2016 | $5,625,000 | | tax credit/rebate |
Merck Sharp & Dohme Corp. | Merck | North Carolina | state | 2004 | $5,514,655 | | grant |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2016 | $5,514,595 | | enterprise zone |
Biogen Idec MA, Inc. | Biogen | Massachusetts | state | 2013 | $5,512,500 | | tax credit/rebate |
Pfizer, Inc. | Pfizer | New York | local | 2007 | $5,510,432 | | tax credit/rebate; property tax abatement |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2014 | $5,509,471 | | enterprise zone |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2014 | $5,509,471 | | enterprise zone |
Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | 2013 | $5,485,485 | | tax credit/rebate |
Janssen Research & Development, LLC ( f/k/a J&J Pharmaceutical Research & Development, LLC) | Johnson & Johnson | Pennsylvania | state | 2012 | $5,461,142 | | tax credit/rebate |
Novo Nordisk, Inc. | Novo Holdings A/S | New Jersey | state | 2007 | $5,405,932 | | grant |
Abbott Laboratories | Abbott Laboratories | Ohio | state | 2012 | $5,369,069 | | tax credit/rebate |
Boehringer Ingelheim Vetmedica, Inc. | Eli Lilly | Iowa | state | 2010 | $5,275,484 | | tax credit/rebate |